Global Market Report From IDTechEx Research on Tissue Engineering 2018-2028: Technologies, Markets, Forecasts

IDTechEx Research forecasts the market for tissue engineered products to exceed $4.8 billion by the year 2028 in their report on the topic.

Tissue engineering, referring to the technologies that use physical, chemical, biological and engineering processes to control and direct the aggregate behavior of cells, has become a field of increasing commercial interest. Though tissue engineering as a field has been around since the late 1970s, there have been few commercial successes. However, human understanding of biology, and our ability to manipulate it has finally reached a point where complex living tissue equivalents are being developed. The IDTechEx Research report Tissue Engineering 2018-2028: Technologies, Markets, Forecasts investigates this next generation of tissue engineering products and their potential in the next 10 years.

This report covers living tissue equivalents which contain both living cells and a 3D structure.

Applications

The biggest applications for engineered tissues are in research and development, and in medicine. This report discusses the following key applications of tissue engineering:

·         Testing of cosmetics and other consumer goods

·         Drug screening

·         Personalized medicine

·         Regenerative medicine

·         Cell-based biosensors

·         Food and other animal products

·         Aesthetics

Clinical Landscape

A chapter of Tissue Engineering 2018-2028: Technologies, Markets, Forecasts is dedicated to the use of tissue engineering products in medicine. The following classes of tissue engineered therapies are highlighted:

·         Tissue engineered therapies with FDA marketing approval

·         Tissue engineered therapies close to IND submission

·         Competitive landscape of tissue-engineered skin

·         Competitive landscape of tissue-engineered cartilage

Additionally, a summary of ongoing clinical trials of tissue engineered products is provided, organized by trial phase, tissue type, and sponsor.

The rest of this chapter describes and discusses the dynamics of US and EU markets, with a look at relevant regulatory pathways, exemptions, and loopholes for tissue engineered products, as well as speculations on the future of regulating this novel class of therapy.

Market Forecasts

A market forecast for tissue engineered products is provided for the years 2018 - 2028, where the total value for tissue engineered products is predicted to surpass $4.8 billion. This market is broken down into key applications of therapies (clinical use) and tissue models (research use). Key players in both applications are presented, and the value chain and relevant business models are discussed.

Separately, a forecast for 3D bioprinters, an up-and-coming technology for tissue engineering, is also provided for the years 2018 - 2028.

Technology

A wide range of approaches are still being explored in tissue engineering, and this report covers both the most innovative and cutting-edge techniques as well as more established technologies. Technologies presented in Tissue Engineering 2018-2028: Technologies, Markets, Forecasts are:

·         Semi-permeable membranes

·         Cell-laden hydrogels

·         3D bioprinting

·         3D printing (including thermoplastic extrusion, material jetting, stereolithography, selective laser sintering)

·         Decellularization and recellularization of organs

·         Phase separation, freeze-drying, solvent casting and particle leaching, gas foaming

·         Electrospinning and melt electrospinning

·         Self-assembly and self-organization

For more information contact the IDTechEx Research team at research@IDTechEx.com or visit www.IDTechEx.com/tissue.

IDTechEx guides your strategic business decisions through its Research, Consultancy, and Events services, helping you profit from emerging technologies. Find out more at www.IDTechEx.com.

Table of Contents Tissue Engineering 2018-2028: Technologies, Markets, Forecasts

1.            EXECUTIVE SUMMARY

1.1.         Overview

1.2.         What is Tissue Engineering?

1.3.         How are Tissues Engineered?

1.4.         Key Players

1.5.         Key Drivers

1.6.         Key Opportunities

1.7.         Tissue Engineered Products Market Forecast 2018 - 2028

1.8.         Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028

1.9.         Tissue Engineered Products for Research Use Market Forecast 2018 - 2028

1.10.      Key Technologies

1.11.      Key Challenges

2.            INTRODUCTION

2.1.         Report Scope

2.2.         Advantages of 3D Cell Culture

2.3.         Key Driver: Regenerative Medicine

2.4.         Key Driver: Unmet Need in Organs for Transplant

2.5.         Key Driver: Product Testing in Medicine

2.6.         Key Driver: Avoiding Costly Drug Trial Failures

2.7.         Key Driver: Product Testing in Consumer Products

2.8.         Current Challenges: Biological

2.9.         Current Challenges: Commercialization

2.10.      Tissue Engineering in 2017

3.            KEY OPPORTUNITIES

3.1.         Overview

3.2.         Testing of Cosmetics and Other Consumer Goods

3.3.         Product Testing: Companies

3.4.         Product Testing:

3.5.         Drug Screening: Dermagenist

3.6.         Drug Screening: Drug Development Process

3.7.         Drug Screening: Benefits of Tissue Engineering

3.8.         Drug Screening: Cancer

3.9.         Drug Screening: Organ-on-a-chip

3.10.      Drug Screening: Companies

3.11.      Personalised Medicine

3.12.      Cell-Based Biosensors

3.13.      Food and Other Animal Products

3.14.      Esthetics

4.            TISSUE ENGINEERING CLINICAL LANDSCAPE

4.1.         Overview

4.2.         Regenerative Medicine

4.3.         Competing Products

4.4.         Competing Products: Advantages and Disadvantages

4.5.         Commercial Activity

4.6.         The US Market

4.7.         Products with FDA Marketing Approval

4.8.         The European Market

4.9.         Clinical Trials

4.10.      Clinical Trials: By Indication and Phase

4.11.      Skin: Clinical Products

4.12.      Cartilage: Clinical Products

4.13.      Cartilage: NeoCart

4.14.      Pre-Clinical Products

4.15.      Regulatory Exemptions

4.16.      Hospital Exemption Scheme

4.17.      Hospital Exemption Scheme: Problems

4.18.      21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation

4.19.      Orphan Drug Designation

4.20.      Scams and Unauthorized Treatments

4.21.      Moving to Conditional Approval

4.22.      Moving to Conditional Approval: Case Study

4.23.      Learning from Medical Innovations

4.24.      Future

5.            MARKETS AND FORECASTS

5.1.         Overview

5.2.         Market Barriers

5.3.         Tissue Engineering Value Chain

5.4.         Tissue Engineering Value Chain: Discussion

5.5.         Forecasts

5.6.         Tissue Engineered Products Market Forecast 2018 - 2028

5.7.         Companies with Marketed Clinical Products

5.8.         Companies Developing Engineered Tissues for Clinical Use

5.9.         Business Models: Engineered Autologous Tissues

5.10.      Business Models: Cryopreserved Allogeneic Tissues

5.11.      Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028

5.12.      Companies Engineering Tissues for Research Use

5.13.      Business Models: Tissues for Research Use

5.14.      Tissue Engineered Products for Research Use Market Forecast 2018 - 2028

5.15.      Companies Producing Organ-On-A-Chips

5.16.      Companies Producing Lab-Grown Meat

5.17.      Scaffold Manufacturers

5.18.      3D Bioprinter Market and Forecasts

5.19.      Growing 3D Bioprinting Market

5.20.      3D Bioprinting Value Chain

5.21.      3D Bioprinting Value Chain: Discussion

5.22.      3D Bioprinters by Cost and Technology

5.23.      3D Bioprinter Market Forecast 2018 - 2028

5.24.      Caveats

6.            TISSUE ENGINEERING TECHNOLOGIES

6.1.         Overview

7.            ESTABLISHED TECHNOLOGIES

7.1.         Introduction

7.2.         Semi-Permeable Membranes

7.3.         Key Semi-Permeable Membrane Manufacturers

7.4.         Hydrogels

7.5.         Cell-Laden Hydrogels

7.6.         Cell-Laden Hydrogels: Companies

7.7.         Cell-Laden Hydrogels: SWOT Analysis

8.            3D BIOPRINTING

8.1.         Introduction

8.2.         3D Bioprinting Process

8.3.         Comparison of Key Specifications

8.4.         3D Bioprinting Technology Comparison

8.5.         Inkjet: Thermal

8.6.         Inkjet: Piezoelectric

8.7.         Inkjet: Companies

8.8.         Inkjet: SWOT Analysis

8.9.         Extrusion: Pneumatic

8.10.      Extrusion: Mechanical

8.11.      Extrusion: Companies

8.12.      Extrusion: Example

8.13.      Extrusion: SWOT Analysis

8.14.      LIFT: Laser-Induced Forward Transfer

8.15.      LIFT: Companies

8.16.      LIFT: SWOT Analysis

8.17.      Microvalve: Solenoid

8.18.      Microvalve: Companies

8.19.      Microvalve: SWOT Analysis

8.20.      Industry-wide Technical Challenges

8.21.      The Ideal 3D Bioprinter

8.22.      Animal Studies

8.23.      Future Technological Directions

9.            SCAFFOLD TECHNOLOGIES

9.1.         Tissue Engineering Scaffolds

9.2.         Ideal Scaffold

10.          3D PRINTING

10.1.      Introduction

10.2.      Examples of 3D Printed Medical Products

10.3.      Thermoplastic Extrusion

10.4.      Thermoplastic Extrusion: Example

10.5.      Thermoplastic Extrusion: Key Manufacturers

10.6.      Thermoplastic Extrusion: SWOT Analysis

10.7.      Material Jetting

10.8.      Material Jetting: Key Players

10.9.      Material Jetting: SWOT Analysis

10.10.    Stereolithography

10.11.    Stereolithography: Key Players

10.12.    Stereolithography: SWOT Analysis

10.13.    Stereolithography: Microstereolithography

10.14.    Stereolithography: Projection

10.15.    Stereolithography: Multiphoton Lithography

10.16.    Stereolithography: Multiphoton Lithography: Example

10.17.    Selective Laser Sintering

10.18.    Selective Laser Sintering: Key Players

10.19.    Selective Laser Sintering: SWOT Analysis

11.          DECELLULARIZED ORGANS

11.1.      Introduction

11.2.      History

11.3.      Decellularization

11.4.      Recellularization

11.5.      Companies

11.6.      Future Technological Directions

11.7.      Bioreactors

12.          OTHER SCAFFOLD TECHNOLOGIES

12.1.      Introduction

12.2.      Phase Separation

12.3.      Freeze-Drying

12.4.      Freeze-Drying: Companies

12.5.      Solvent Casting and Particle Leaching

12.6.      Gas Foaming

12.7.      Chemical Processes: Strengths and Weaknesses

12.8.      Textile Technologies

12.9.      Electrospinning

12.10.    Cell Electrospinning

12.11.    Electrospinning: Examples

12.12.    Electrospinning: SWOT Analysis

12.13.    Melt Electrospinning

12.14.    Melt Electrospinning: SWOT Analysis

12.15.    Electrospinning: Companies

13.          SCAFFOLDLESS TECHNOLOGIES

13.1.      Introduction

13.2.      Cell Spheroids

13.3.      Cell Spheroids: Self-Assembly

13.4.      Cell Spheroids: Self-Organization

13.5.      Cell Spheroids: Rotational Culture Equipment

13.6.      Cell Spheroids: Key Companies

13.7.      Cell Sheets

13.8.      Cell Therapy Devices

13.9.      Cell Therapy Devices: Companies

14.          TISSUE ENGINEERING CHALLENGES

14.1.      Industry-Wide Technical Challenges

14.2.      Biopreservation

14.3.      Vascularization

15.          COMPANY PROFILES

15.1.      3D Bioprinting Solutions/ Vivax Bio

15.2.      3D Biotek

15.3.      3Dynamic Systems Ltd

15.4.      Aether Inc.

15.5.      Aspect Biosystems

15.6.      ATERA

15.7.      Avery Therapeutics

15.8.      AxoSim

15.9.      BioBots

15.10.    BioDan Group

15.11.    BIOLIFE4D

15.12.    Cellenion SASU

15.13.    Cellf BIO

15.14.    Cellink

15.15.    CUTISS

15.16.    Digilab Inc.

15.17.    GeSiM

15.18.    Hesperos

15.19.    Histogenics

15.20.    Lena Biosciences

15.21.    Microdrop Technologies GmbH

15.22.    MicroFab Technologies

15.23.    Mimetas

15.24.    PeptiGel Design Ltd

15.25.    Poietis

15.26.    Prellis Biologics

15.27.    Regemat 3D

15.28.    RegenHU

15.29.    SE3D

15.30.    Sichuan Revotek Co. Ltd.

15.31.    Synthecon

15.32.    Tara Biosystems

15.33.    TissUse

15.34.    Upside Biotechnologies

Media Contact:
Charlotte Martin
Marketing & Research Co-ordinator
c.martin@IDTechEx.com
+44(0)1223 812300

Source: IDTechEx


Categories: Biology, Pharmaceuticals and Biotech

Tags: bioengineered tissue, business intelligence, global research, living tissue equivalents, market forecasts, medical technology, regenerative medicine, tissue engineered products, tissue engineered therapies, tissue engineering


About IDTechEx

View Website

Since 1999 IDTechEx has provided independent market research, business intelligence and events on emerging technology to clients in over 80 countries.